SLGL
HealthcareSol-Gel Technologies Ltd.
$44.19
+$2.04 (+4.84%)
Jan 5, 2026
Price History (1Y)
Analysis
Sol-Gel Technologies Ltd. is a healthcare company within the biotechnology industry with a relatively small scale, employing 34 people and having a market capitalization of $123.10 million. The company's financial health indicates significant challenges, with negative profitability metrics: gross margin at -28.7%, operating margin at -1572.0%, and profit margin at -47.4%. Returns on equity and assets are also negative, standing at -29.6% and -16.5%, respectively. The balance sheet shows a moderate level of debt ($1.08 million) compared to cash ($20.84 million), resulting in a debt-to-equity ratio of 4.16. The company's valuation metrics suggest a negative P/E ratio, forward P/E of -6.49, and EV/EBITDA of -10.26. Revenue growth has been substantial but negative at -92.5% year-over-year.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Visit website →Key Statistics
- Market Cap
- $123.10M
- P/E Ratio
- N/A
- 52-Week High
- $52.26
- 52-Week Low
- $4.02
- Avg Volume
- 18.01K
- Beta
- 1.36
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- Israel
- Employees
- 34